The Trump administration is reportedly considering a major shift in health care coverage allowing Medicare and Medicaid to cover popular weight loss drugs like Ozempic, Wegovy, Mounjaro and Zepbound as early as April 2026
Our research is helping build the future of GLP-1 care, advancing the science so we can develop smarter, more personalized Microdosing GLP-1 protocols built for disease prevention and longevity
Tirzepatide is the first dual GIP receptor agonist and GLP-1 receptor agonist
Whether youre managing diabetes, trying to support weight loss, or simply looking to boost your glow from within, understanding how GLP-1 affects the skin can help you make more informed choices.
This strategy demonstrated significant efficacy, increasing sensitivity in resistant organoids by 20%
Focus on gradual, sustainable weight loss through a combination of healthy eating and regular exercise